TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) today. The company’s shares opened today at $34.78. According to TipRanks, Nadeau is a 4-star
TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) today. The company’s shares opened today at $34.78. According to TipRanks, Nadeau is a 4-star
Xoma (XOMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock
H.C. Wainwright raised the firm’s price target on Xoma (XOMA) to $123 from $117 and keeps a Buy rating on the shares after the company acquired Pulmokine and its interest
ההחלטה הזו התקבלה בעקבות רכישת Pulmokine על ידי Xoma והתעניינותם בסרלוטיניב, אשר מפותח לטיפול ביתר לחץ דם ריאתי. האנליסט מסביר למשקיעים בהערת מחקר כי הוספת סרלוטיניב לבסיס התמלוגים הנרחב של
XOMA (XOMA) Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension through its acquisition of Pulmokine Inc., a privately held